Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Director | July 01, 2022 | July 01, 2022 |
| Moderna, Inc.MRNA · Entity 2025 | Chief Medical Officer | June 30, 2021 | July 02, 2021 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | August 05, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date July 01, 2022 · Filed July 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2032-07-01 | Direct | 500,000 |
Reported balance
After 2022-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-01 · Grant · Acquired 500,000 · Balance 500,000 F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.
Moderna, Inc.
Report date June 30, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-06-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-06-30 · Exercise / conversion · Acquired 5,000 · Balance 5,000 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021. Row 2 · 2021-06-30 · Sale · Disposed 5,000 · Balance 0 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.93 · Expires 2030-02-28 | Direct | 121,120 |
Reported balance
After 2021-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-30 · Exercise / conversion · Disposed 5,000 · Balance 121,120 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021. F2: 25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021.
F2: 25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date August 05, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 73,247 |
Reported balance
After 2026-08-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-05 · Sale · Disposed 17 · Balance 73,247 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 8,690 | $65.35 | $567,891.50 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,158 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.02 to $66.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 9,849 | $64.56 | $635,851.44 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,848 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.01 to $65.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,303 | $63.65 | $210,235.95 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,697 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.98 to $63.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-023815 · form4.xml · derivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-20-023815 · form4.xml · derivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:24 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 20,000 | $69.06 | $1,381,200.00 |
DisclosureSEC source: 0001127602-20-023815 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-023815 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0001127602-20-023815 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:31 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-023384 · form4.xml · derivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:31 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-20-023384 · form4.xml · derivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:31 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 20,000 | $74.27 | $1,485,400.00 |
DisclosureSEC source: 0001127602-20-023384 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:31 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-023384 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:31 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0001127602-20-023384 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-022719 · form4.xml · derivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-20-022719 · form4.xml · derivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 20,000 | $74.89 | $1,497,800.00 |
DisclosureSEC source: 0001127602-20-022719 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-022719 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0001127602-20-022719 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-022237 · form4.xml · derivative · entry 9 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F7 · derivative.exercise_date: This option is fully vested and exercisable. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-20-022237 · form4.xml · derivative · entry 8 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 900 | $80.43 | $72,387.00 |
DisclosureSEC source: 0001127602-20-022237 · form4.xml · nonDerivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.27 to $80.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 7,228 | $79.72 | $576,216.16 |
DisclosureSEC source: 0001127602-20-022237 · form4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.22 to $80.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,548 | $78.73 | $436,794.04 |
DisclosureSEC source: 0001127602-20-022237 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,128 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.21 to $79.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,940 | $77.68 | $306,059.20 |
DisclosureSEC source: 0001127602-20-022237 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,676 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.20 to $78.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,384 | $76.79 | $183,067.36 |
DisclosureSEC source: 0001127602-20-022237 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,616 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $76.19 to $77.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-022237 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:41 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0001127602-20-022237 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · derivative · entry 15 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F12 · derivative.exercise_date: This option is fully vested and exercisable. F13 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · derivative · entry 14 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 200 | $90.64 | $18,128.00 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 13 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 400 | $88.76 | $35,504.00 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 12 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.59 to $88.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 354 | $87.41 | $30,943.14 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 11 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.05 to $87.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,000 | $86.37 | $86,370.00 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 10 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.98 to $86.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,469 | $85.58 | $296,877.02 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 9 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,954 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.97 to $85.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,409 | $84.53 | $203,632.77 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 8 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,423 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.96 to $84.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,425 | $83.17 | $284,857.25 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,832 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.82 to $83.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,488 | $82.49 | $370,215.12 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,257 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.81 to $82.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,205 | $81.23 | $179,112.15 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,745 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.80 to $81.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,650 | $80.49 | $132,808.50 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,950 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.77 to $80.76 Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 400 | $78.77 | $31,508.00 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,600 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.41 to $79.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 00:43 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0001127602-20-021918 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 21:01 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-021496 · form4.xml · derivative · entry 17 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F15 · derivative.exercise_date: This option is fully vested and exercisable. F16 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 21:01 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-20-021496 · form4.xml · derivative · entry 16 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 21:01 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 200 | $77.54 | $15,508.00 |
DisclosureSEC source: 0001127602-20-021496 · form4.xml · nonDerivative · entry 15 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.44 to $77.63. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 21:01 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 200 | $76.12 | $15,224.00 |
DisclosureSEC source: 0001127602-20-021496 · form4.xml · nonDerivative · entry 14 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $76.11 to $76.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 21:01 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 737 | $75.45 | $55,606.65 |
DisclosureSEC source: 0001127602-20-021496 · form4.xml · nonDerivative · entry 13 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.02 to $75.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.